CombGeneTher
Gene-Independent Combination Therapy for Rod-Cone Dystrophy
Universal combination therapy for inherited retinal degenerations
Features
Project duration
36 months
Start :
End :
Project scale
European project
Allocated budget
211 754,88 €
Description
Universal combination therapy for inherited retinal degenerations
Rod-cone dystrophies are inherited retinal diseases in which rod photoreceptor degeneration leads to complete blindness. Gene replacement therapy is successful in treating some inherited retinal degenerations only if the underlying mutation is known and recessive. All rod-cone dystrophies display a common phenotype of rod cell loss, followed by initial cone cell degeneration in the periphery and then in the fovea. Gene therapy, counteracting the symptoms of rod-cone dystrophy has the potential to be helpful in the highest number of affected patients. Funded by the Marie Skłodowska-Curie Actions programme, the CombGeneTher project aims to develop a combination gene therapy to restore light sensitivity in mouse models of rod-cone dystrophies.
Programme
Horizon Europe
Horizon Europe is the European Union's framework program for research and innovation for the period 2021-2027. Horizon Europe takes over from Horizon 2020, which ends at the end of 2020.
MSCA Postdoc fellowship
The objective of PFs is to support researchers’ careers and foster excellence in research. The Postdoctoral Fellowships action targets researchers holding a PhD who wish to carry out their research activities abroad, acquire new skills and develop their careers. PFs help researchers gain experience in other countries, disciplines and non-academic sectors.
Project team
Partners
